Lifevantage (NASDAQ:LFVN) reported fiscal third-quarter 2026 results that reflected a sharp year-over-year revenue decline, as management pointed to weaker demand for its MindBody GLP-1 System and ...

A new study from the University of Virginia reveals that a widely used class of weight-loss drugs does more than suppress appetite-it directly alters brain circuits that control motivation and reward.

The success of GLP-1 drugs is reshaping discussion around endometriosis treatment and the future of the women’s health market ...

Millions of people with Medicare will soon be eligible to get discounted GLP-1 drugs for weight loss. Here's how it will work ...

Gross profit margin -- 79%, down from 81%, with higher shipping, warehouse, and inventory obsolescence costs; adjusted ...

Q3 2026 Earnings Call May 6, 2026 4:30 PM EDTCompany ParticipantsMichael Beindorff - Interim CEO & DirectorCarl Aure ...

SINGAPORE - Media OutReach Newswire - 7 May 2026 - Dr. Terence Tan, Medical Director of Halley Medical Aesthetics and Halley ...

LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal ...

Scientists have unveiled OBSCORE, a predictive tool that estimates a person’s 10-year risk of developing 18 obesity-related diseases using 20 key health indicators. The system could help prioritise ...

THREE women from the same family who live in the UK’s fat jab capital have shed a staggering 20st all in – and know how to ...

A growing number of women are diagnosed each year with breast cancer. Breast cancer diagnoses are increasing at a rate of 1% per ...

Here are the 10 worst-performing stocks so far in 2026 among companies that trade on major U.S. exchanges and have market ...